COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO

Protocol No
ALLIANCE-ALCHEMIST-A081801
Principal Investigator
Jonathan Thompson
Phase
III
Summary
This study is being done to answer the following question: Can we lower the chance of your lung cancer coming back by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach is defined as care most people get for non-small cell lung cancer
Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category